Endometrial preparation for in vitro oocyte maturation: Early use of estrogen increases endometrial tissue and requires lower daily dosage: A cross over trial in ‘mock’ cycles

Abstract

Purpose: Determine if estrogen used since the beginning of the menstrual flow could improve endometrial tissue compared to standard endometrial preparation for in vitro maturation cycles.Methods: Twenty polycystic ovary syndrome women were submitted to two estrogen therapy schedules: standard schedule; estrogen began on the day of planned egg retrieval (dosage was based on endometrial thickness); and long schedule; estrogen began on the first day of menstruation. No oocyte retrieval or embryo transfer was performed. Three-dimensional ultrasound was performed on the day of planned egg retrieval and one week later for endometrial evaluation.Results: A higher endometrial thickness and volume was found in long schedule on both evaluations. The number of patients that have used 10 mg/day of estradiol was significant higher in the standard schedule (65% × 0%). No other significant difference was found.Conclusions: The early use of estrogen improves endometrial tissue and requires lower daily dosage.

Supplemented tissue culture medium 199 is a better medium for in vitro maturation of oocytes from women with polycystic ovary syndrome women than human tubal fluid

“…On this day, endometrial thickness was assessed, and when it was <8 mm the E 2 valerate dosage was increased to 10 mg/day; if it was >8 mm the dose of 6 mg/day was maintained. This endometrial preparation schedule is performed in our service because it has been shown to increase endometrial thickness and to prevent most women from using the higher estrogen dose of 10 mg/day (10). After ET, the luteal phase was supplemented with 30 mg/day of dydrogesterone (Duphaston; Solvay Pharmaceuticals, Pymble, New South Wales, Australia).…”